Archer C, Randhawa M, Kim H, et al. Real world data on intensive follow-up for stage IV metastatic melanoma patients receiving ipilimumab and nivolumab: a safer model of care? SMR 2017, abstract P07-1.
Tucatinib verlengt mediane overleving met 5,5 maand in finale analyse HER2CLIMB-studie
mrt 2022 | Borstkanker